benzyl 9-hydroxynonanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 9-hydroxynonanoate
• 英文别名: Benzyl 9-hydroxynonanoate
• 化学式: C₁₆H₂₄O₃
• 分子量: 264.365
• InChiKey: GWMVWNSLYDVOSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl 9-hydroxynonanoate 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 9-aminononanoyl-Arg-Arg-Arg-COOH
  参考文献：
  名称：

  Targeting the tubulin C-terminal tail by charged small molecules

  摘要：

  一系列带有三个精氨酸的线性和环状肽被合成，以结合微管C末端尾部，为针对这个多才多艺但难以药物化靶点提供了起点。

  DOI：

  10.1039/d2ob01910h
• 作为产物：
  描述：

  壬二酸 在 硼烷四氢呋喃络合物 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 生成 benzyl 9-hydroxynonanoate
  参考文献：
  名称：

  Targeting the tubulin C-terminal tail by charged small molecules

  摘要：

  一系列带有三个精氨酸的线性和环状肽被合成，以结合微管C末端尾部，为针对这个多才多艺但难以药物化靶点提供了起点。

  DOI：

  10.1039/d2ob01910h

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：PHOTOCURE ASA

  公开号：WO2014020164A1

  公开（公告）日：2014-02-06

  The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for preparing such compounds and their medical and cosmetic use, for example in methods of photodynamic therapy and diagnosis: wherein R1 represents a hydrogen atom or an optionally substituted alkyl or cycloalkyl group; R2, each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group; and X is a linking group.

  这项发明涉及5-氨基丙酮酸（5-ALA）的新衍生物及其用作光敏剂的用途。具体而言，涉及到一般式I的化合物及其药学上可接受的盐，以及制备这些化合物的方法及它们在医药和化妆品中的用途，例如在光动力疗法和诊断方法中：其中R1代表氢原子或可选择取代的烷基或环烷基基团；R2，每个可能相同或不同，代表氢原子或可选择取代的烷基基团；X是一个连接基。
• Compounds
  申请人：Photocure ASA

  公开号：US20150191419A1

  公开（公告）日：2015-07-09

  The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for preparing such compounds and their medical and cosmetic use, for example in methods of photodynamic therapy and diagnosis: wherein R 1 represents a hydrogen atom or an optionally substituted alkyl or cycloalkyl group; R 2 , each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group; and X is a linking group.

  本发明涉及5-氨基戊酸（5-ALA）的新衍生物及其作为光敏剂的用途。特别地，涉及通式I的化合物及其药学上可接受的盐，用于制备此类化合物的方法以及它们在医学和美容上的应用，例如在光动力疗法和诊断方法中：其中R1代表氢原子或可选择取代的烷基或环烷基；R2，每个可能相同或不同，代表氢原子或可选择取代的烷基；而X是连接基。
• Carboxylic acid ALA esters
  申请人：Photocure ASA

  公开号：US09249086B2

  公开（公告）日：2016-02-02

  The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for preparing such compounds and their medical and cosmetic use, for example in methods of photodynamic therapy and diagnosis: wherein R1 represents a hydrogen atom or an optionally substituted alkyl or cycloalkyl group; R2, each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group; and X is a linking group.

  本发明涉及5-氨基戊酸（5-ALA）的新衍生物及其作为光敏剂的用途。具体而言，涉及一般式I的化合物及其药学上可接受的盐，制备这种化合物的方法以及它们在医疗和美容上的用途，例如在光动力疗法和诊断方法中使用：其中，R1代表氢原子或可选择取代的烷基或环烷基；R2分别可以相同或不同，代表氢原子或可选择取代的烷基；而X是连接基。
• [EN] DEGRADATION AGENTS FOR CYCLIN DEPENDENT KINASE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE KINASE DÉPENDANTE DE LA CYCLINE, LEUR PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE DE CEUX-CI ET UTILISATION ASSOCIÉE<br/>[ZH] 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2020035049A1

  公开（公告）日：2020-02-20

  公开了通式(I)所示的靶向细胞周期依赖性激酶(CDKs)降解剂的化合物和/或其药学上可接受的盐、其药物组合物以及这些衍生物作为药物活性剂，用于预防和/或治疗CDKs异常活性相关的疾病的药物中的用途。所述化合物对实体肿瘤和血液肿瘤均具有较好的抑制细胞增殖的效果，说明具有潜在的治疗相关癌症和自身免疫性疾病的潜力。
• Synthesis of a Structurally Defined Antigen-Immunostimulant Combination for Use in Cancer Vaccines
  作者：Wulf Dullenkopf、Gerd Ritter、Sheila R. Fortunato、Lloyd J. Old、Richard R. Schmidt

  DOI：10.1002/(sici)1521-3765(19990802)5:8<2432::aid-chem2432>3.0.co;2-5

  日期：1999.8.2

  Ganglioside GM(2) expressed on the cell surface of human cancers is a promising target for immunotherapy because GM(2) antibodies are cytotoxic in vitro and GM(2) antibody formation can be induced upon vaccination in cancer patients. We recently reported on the efficient chemical synthesis of GM(2); clinical trials with these synthetic GM(2) conjugated to a purified carrier protein (KLH) are currently under way. In our efforts to generate a totally synthetic GM(2) cancer vaccine, we have now synthesized GM(2) neoglycolipid 1, which consists of the GM(2)-tetrasaccharide epitope that is linked through a spacer to the B-cell stimulatory glycolipid 4. Target compound 1 was constructed from the GM(2) tetrasaccharide donor 2, the 9-hydroxynonanoate 3 spacer, and the 6-amino-6-deoxy derivative (5) of compound 4. Building block 5 was obtained from Z-protected 6-azido-6-deoxy-N-leucyl-glucosamine derivative 12, which was available from glucosamine by two different approaches; the route with the Z-protected derivative of 4 (10) as intermediate gave the best yields, The neoglycolipid 1 reacted with a number of different GM(2)-reactive antibodies. Vaccination of rabbits with 1 resulted in induction of antibodies against GM(2), thus confirming the viability of this novel concept far the construction of a totally synthetic vaccine.